TiGenix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.09.16	TiGenix Appoints Dr. June Almenoff to its Board of Directors (GlobeNewswire)
20.09.16	TiGenix Business and Financial Update for the First Half 2016 (GlobeNewswire)
02.08.16	Takeda & TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease (GlobeNewswire)
20.07.16	Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix (GlobeNewswire)
05.07.16	Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease (GlobeNewswire)
05.07.16	TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms (GlobeNewswire)
17.06.16	TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction (GlobeNewswire)
16.06.16	TiGenix CEO Eduardo Bravo assumes leadership of European Biopharmaceutical Enterprises (EBE) (GlobeNewswire)
18.05.16	TiGenix Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA (GlobeNewswire)
03.05.16	TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 2 JUNE 2016 (GlobeNewswire)
12.04.16	TiGenix: TiGenix reports 2015 full year results (GlobeNewswire)
18.03.16	TiGenix: Notice in relation to the convertible bonds due 2018 (GlobeNewswire)
17.03.16	TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016 (GlobeNewswire)
07.03.16	TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients (GlobeNewswire)
02.03.16	TiGenix: TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients (GlobeNewswire)
23.02.16	TiGenix obtains commercial production license for Cx601 (GlobeNewswire)
11.01.16	TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress (GlobeNewswire)
08.01.16	TiGenix participates in key conferences in the first half of 2016 (GlobeNewswire)
22.12.15	TiGenix files Registration Statement for proposed initial public offering in the United States (GlobeNewswire)
19.11.15	TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction (GlobeNewswire)
02.11.15	TiGenix: SEPCELL project in severe sepsis receives €5.4M grant from the EU's Horizon 2020 (GlobeNewswire)
23.09.15	TiGenix: AlloCSC-01 Phase I data Presented at the Congress of the European Society of Cardiology (GlobeNewswire)
15.09.15	TiGenix Business and Financial Update for the First Half of 2015 (GlobeNewswire)
10.09.15	TiGenix : TiGenix to host webcast for its 2015 half-year results on 15 September (GlobeNewswire)
09.09.15	TiGenix : Tigenix to participate or present at key conferences in H2 2015 (GlobeNewswire)
23.08.15	TiGenix :TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial (GlobeNewswire)
07.08.15	TiGenix obtains FDA's endorsement through Special Protocol Assessment for its Cx601 Phase III registration trial in the US (GlobeNewswire)
31.07.15	TiGenix: Dirk Büscher and José Terencio resign from TiGenix board of directors (GlobeNewswire)
30.07.15	TiGenix: TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition (GlobeNewswire)
03.07.15	TiGenix: Notice in relation to the convertible bonds due 2018 (GlobeNewswire)
11.06.15	TiGenix: TiGenix starts Cx601 Marketing Authorisation Application process (GlobeNewswire)
28.05.15	TiGenix: Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial (GlobeNewswire)
13.05.15	TiGenix: Notice in relation to the convertible bonds due 2018 (GlobeNewswire)
13.05.15	TiGenix:CONVENING NOTICE TO THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 2 JUNE 2015 (GlobeNewswire)
08.04.15	TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas (GlobeNewswire)
20.03.15	TiGenix: CONVENING NOTICE TO THE ANNUAL AND THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 20 APRIL 2015 (GlobeNewswire)
20.03.15	TiGenix: CONVENING NOTICE TO THE ANNUAL AND THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 20 APRIL 2015 (GlobeNewswire)
17.03.15	TiGenix: TiGenix reports its full year 2014 results (GlobeNewswire)
12.03.15	TiGenix: TiGenix completes treatment in Phase I sepsis challenge trial with Cx611 (GlobeNewswire)
23.02.15	TiGenix: TiGenix's Phase III trial design for Cx601 endorsed by President-Elect of ECCO (GlobeNewswire)
12.02.15	TiGenix: TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn's disease (GlobeNewswire)
02.02.15	TiGenix: TiGenix participates in key conferences in the first half of 2015 (GlobeNewswire)
22.01.15	TiGenix: European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions (GlobeNewswire)
22.12.14	TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment (GlobeNewswire)
10.12.14	TiGenix starts Phase I trial of Cx611 in severe sepsis (GlobeNewswire)
12.11.14	TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule (GlobeNewswire)
04.11.14	TiGenix: Business and Financial Update for the third quarter of 2014 (GlobeNewswire)
17.10.14	TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (GlobeNewswire)
15.09.14	TiGenix: TiGenix to participate or present at key conferences in the second half of 2014 (GlobeNewswire)
08.09.14	European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.38	2.91 %	K V
Part Grp Hldg	1’323.50	1.89 %	K V
Roche Hldg G	270.90	1.50 %	K V
Givaudan	3’926.00	1.13 %	K V
Novartis	91.74	0.86 %	K V
Geberit	503.00	-0.55 %	K V
CieFinRichemont	139.95	-0.71 %	K V
Swiss Re	133.65	-0.85 %	K V
Zurich Insur Gr	542.20	-0.91 %	K V
Kuehne+Nagel Int	201.80	-2.70 %	K V

Nachrichten zu TiGenix S.A.

Aktien Top/Flop

Meistgelesene Nachrichten